Lymphoma drug trial halted after researchers fail to find safe dose

NCT ID NCT05403450

Summary

This study aimed to test the safety and find the right dose of a new drug combination (tolinapant plus oral decitabine/cedazuridine) for adults with a rare and aggressive blood cancer that had returned or stopped responding to prior treatments. The trial was stopped early after the initial phase because researchers could not identify a dose that was both safe and tolerable for patients. Therefore, the planned second phase to test how well the combination worked was not conducted.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AP-HP Pitie Saltpetriere Site# 552

    Paris, 75013, France

  • Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia Site#650

    Brescia, 25123, Italy

  • Barbara Ann Karmanos Cancer Institute Site#159

    Detroit, Michigan, 48201, United States

  • CHU Saint-Eloi Site#556

    Montpellier, 34295, France

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre Henri Becquerel

    Rouen, Seine-Maritime, 76038, France

  • City of Hope Site #151

    Duarte, California, 91010, United States

  • Concord Hospital

    Concord, New South Wales, 2139, Australia

  • Fondazione IRCCS San Gerardo dei Tintori Site #655

    Monza, 20900, Italy

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Guy's and Saint Thomas' NHS Foundation Trust

    London, England, SE1 9Rt, United Kingdom

  • Hospital Universitario 12 de Octubre Site#710

    Madrid, 28041, Spain

  • Hospital Universitario Fundación Jiménez Díaz Site #703

    Madrid, 28040, Spain

  • Hospital Universitario Marqués de Valdecilla Site#711

    Santander, 39008, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Andalusia, 41013, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Catalonia, 8025, Spain

  • Hospital del Mar Site #704

    Barcelona, 08003, Spain

  • Hôpital Bretonneau

    Tours, Indre-et-Loire, 37000, France

  • Institut Bergonié Site#553

    Bordeaux, 33000, France

  • Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)

    Barcelona, Catalonia, 8908, Spain

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Paoli-Calmettes

    Marseille, 13009, France

  • Istituto Europeo di Oncologia Site#652

    Milan, 20141, Italy

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST

    Meldola, Forli-Cesena, 47014, Italy

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

  • Linear Clinical Research Site #834

    Nedlands, 6009, Australia

  • Moffitt Cancer Center Site #157

    Tampa, Florida, 33612, United States

  • Monash Medical Center

    Melbourne, Victoria, 3168, Australia

  • NYU Langone Laura and Isaac Perlmutter Cancer Center Site #153

    New York, New York, 10016, United States

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy

    Warsaw, Masovia, 02-781, Poland

  • Ospedale Santa Maria delle Croci di Ravenna

    Ravenna, Emilia-Romagna, 48121, Italy

  • Ośrodek Badań Klinicznych Wczesnych Faz - Uniwersyteckie Centrum Kliniczne w Gdańsku

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Rochester Skin Lymphoma Medical Group, PLLC Site #147

    Fairport, New York, 14450, United States

  • Stanford University

    Stanford, California, 94305, United States

  • The Christie NHS Foundation Trust

    Manchester, England, M20 4BX, United Kingdom

  • The University of Texas MD Anderson Cancer Center Site #101

    Houston, Texas, 77030, United States

  • U.O.C. di Ematologia Pad. 8IRCCS Azienda OspedalieroUniversitaria di Bologna Site#651

    Bologna, 40138, Italy

  • University College London Hospitals NHS Foundation Trust

    London, England, W1T 7HA, United Kingdom

  • University of Califonia, Los Angeles

    Los Angeles, California, 90095, United States

  • University of Colorado Anschutz Medical Campus Site #118

    Aurora, Colorado, 80045, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania Site# 160

    Philadelphia, Pennsylvania, 19104, United States

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia, 22908, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, 30322, United States

  • Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi

    Lodz, Łódź Voivodeship, 93-513, Poland

  • Yale Cancer Center Site #109

    New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.